Search Results

There are 35040 results for: content related to: Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study

  1. Pharmacokinetics and Absolute Bioavailability of Selegiline Following Treatment of Healthy Subjects With the Selegiline Transdermal System (6 mg/24 h): A Comparison With Oral Selegiline Capsules

    The Journal of Clinical Pharmacology

    Volume 47, Issue 10, October 2007, Pages: 1256–1267, Dr Albert J. Azzaro, Dr John Ziemniak, Ms Eva Kemper, Dr Bryan J. Campbell and Dr Chad VanDenBerg

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007304779

  2. Selegiline for Alzheimer's disease

    Intervention Review

    The Cochrane Library

    Jacqueline Birks and Leon Flicker

    Published Online : 20 JAN 2003, DOI: 10.1002/14651858.CD000442

  3. Monoamine oxidase B inhibitors for early Parkinson's disease

    Intervention Review

    The Cochrane Library

    Kristian Turnbull, Robert Caslake, Angus Macleod, Natalie Ives, Rebecca Stowe and Carl Counsell

    Published Online : 20 JUL 2005, DOI: 10.1002/14651858.CD004898.pub2

  4. A review of the pharmacology of selegiline

    Acta Neurologica Scandinavica

    Volume 84, Issue S136, October 1991, Pages: 44–59, E. H. Heinonen and R. Lammintausta

    Version of Record online : 29 JAN 2009, DOI: 10.1111/j.1600-0404.1991.tb05020.x

  5. Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of Monoamine Oxidase Type B in Humans

    The Journal of Clinical Pharmacology

    Volume 37, Issue 7, July 1997, Pages: 602–609, Dr. Esa H. Heinonen, Mr. Markku I. Anttila, Mr. Hari L. Karnani, Ms. Leena M. Nyman, Mr. Jouni A. Vuorinen, Dr. Kaija A. Pyykkö and Dr. Risto A. S. Lammintausta

    Version of Record online : 8 MAR 2013, DOI: 10.1002/j.1552-4604.1997.tb04342.x

  6. SELEDO: a 5-y-ear long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa

    European Journal of Neurology

    Volume 6, Issue 2, March 1999, Pages: 141–150, H. Przuntek, B. Conrad, J. Dichgans, P.H. Kraus, P. Krauseneck, G. Pergande, U. Rinne, K. Schimrigk, J. Schnitker and H.P. Vogel

    Version of Record online : 27 JUL 2007, DOI: 10.1111/j.1468-1331.1999.tb00007.x

  7. You have free access to this content
    Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids

    British Journal of Clinical Pharmacology

    Volume 47, Issue 3, March 1999, Pages: 249–254, Kari Laine, Markku Anttila, Antti Helminen, Hari Karnani and Risto Huupponen

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.1999.00891.x

  8. Selegiline as the primary treatment of Parkinson's disease — a long-term double-blind study

    Acta Neurologica Scandinavica

    Volume 95, Issue 4, April 1997, Pages: 211–218, V. V. Myllylä, K. A. Sotaniemi, P. Hakulinen, O. Mäki-lkola and E. H. Heinonen

    Version of Record online : 29 JAN 2009, DOI: 10.1111/j.1600-0404.1997.tb00101.x

  9. Selegiline Transdermal System: An Examination of the Potential for CYP450-Dependent Pharmacokinetic Interactions With 3 Psychotropic Medications

    The Journal of Clinical Pharmacology

    Volume 47, Issue 2, February 2007, Pages: 146–158, Dr Albert J. Azzaro, Dr John Ziemniak, Ms Eva Kemper, Dr Bryan J. Campbell and Dr Chad VanDenBerg

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270006296151

  10. Evaluation of the Potential for Pharmacodynamic and Pharmacokinetic Drug Interactions Between Selegiline Transdermal System and Two Sympathomimetic Agents (Pseudoephedrine and Phenylpropanolamine) in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 47, Issue 8, August 2007, Pages: 978–990, Dr. Albert J. Azzaro, Dr. Chad M. VanDenBerg, Dr. John Ziemniak, Ms Eva M. Kemper, Dr. Lawrence F. Blob and Dr. Bryan J. Campbell

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007302950

  11. You have free access to this content
    Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease

    British Journal of Clinical Pharmacology

    Volume 74, Issue 2, August 2012, Pages: 284–295, Thuy C. Vu, John G. Nutt and Nicholas H. G. Holford

    Version of Record online : 10 JUL 2012, DOI: 10.1111/j.1365-2125.2012.04208.x

  12. Monoamine Oxidase-B Inhibition in the Treatment of Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 27, Issue 12P2, December 2007, Pages: 174S–185S, Dr. Hubert H. Fernandez and Dr. Jack J. Chen

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.27.12part2.174S

  13. Selegiline in the treatment of Parkinson's disease

    Acta Neurologica Scandinavica

    Volume 80, Issue s126, November 1989, Pages: 103–111, Heinonen E H and Rinne U K

    Version of Record online : 29 JAN 2009, DOI: 10.1111/j.1600-0404.1989.tb01789.x

  14. Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 46, Issue 8, August 2006, Pages: 933–944, Dr Albert J. Azzaro, Dr Chad M. VanDenBerg, Dr Lawrence F. Blob, Ms Eva M. Kemper, Dr Melvin Sharoky, Dr Dan A. Oren and Dr Bryan J. Campbell

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270006289852

  15. Selegiline can mediate neuronal rescue rather than neuronal protection

    Movement Disorders

    Volume 8, Issue S1, 1993, Pages: S20–S30, Prof. W. G. Tatton

    Version of Record online : 12 OCT 2004, DOI: 10.1002/mds.870080506

  16. You have free access to this content
    Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat

    British Journal of Pharmacology

    Volume 149, Issue 6, November 2006, Pages: 647–656, J P M Finberg, A Gross, O Bar-Am, R Friedman, Y Loboda and M B H Youdim

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0706908

  17. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study

    Movement Disorders

    Volume 19, Issue 4, April 2004, Pages: 426–432, Cheryl H. Waters, Kapil D. Sethi, Robert A. Hauser, Eric Molho and John M. Bertoni

    Version of Record online : 10 FEB 2004, DOI: 10.1002/mds.20036

  18. You have free access to this content
    Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline

    British Journal of Pharmacology

    Volume 143, Issue 3, October 2004, Pages: 371–378, Zaid A Abassi, Ofer Binah and Moussa B H Youdim

    Version of Record online : 17 FEB 2009, DOI: 10.1038/sj.bjp.0705962

  19. Marked Effect of Liver and Kidney Function on the Pharmacokinetics of Selegiline

    Clinical Pharmacology & Therapeutics

    Volume 77, Issue 1, January 2005, Pages: 54–62, Markku Anttila, Eero A. Sotaniemi, Olavi Pelkonen and Arja Rautio

    Version of Record online : 16 JAN 2005, DOI: 10.1016/j.clpt.2004.09.004

  20. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease

    Acta Neurologica Scandinavica

    Volume 91, Issue 3, March 1995, Pages: 177–182, V. V. Myllylä, E. H. Heinonen, J. A. Vuorinen, O.I. Kilkku and K. A. Sotaniemi

    Version of Record online : 29 JAN 2009, DOI: 10.1111/j.1600-0404.1995.tb00429.x